Research progress of GLP-1RAs in the treatment of type 2 diabetes mellitus
Xu He, Wei Zhao, PeiHang Li, YinJiang Zhang, GuoHua Li, HongYu Su, BiNan Lu, ZongRan Pang · 2025
Read Research progress of GLP-1RAs in the treatment of type 2 diabetes mellitus by Xu He, Wei Zhao, PeiHang Li, YinJiang Zhang, GuoHua Li, HongYu Su, BiNan Lu, ZongRan Pang (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11788294.txt.
Description
Xu He and seven co-authors review how GLP-1 receptor drugs work against type 2 diabetes, in this article published in 2024. The drugs copy a gut hormone that nudges the pancreas to release insulin, calms glucagon, slows the stomach, and trims appetite. Unlike the natural hormone, they resist the enzyme that would chew them up, so each dose lasts.
The review walks through the drug family's benefits as the authors see them. Beyond lowering blood sugar and long-term control markers, the drugs protect heart, nerves, and kidneys in the cited work, without the weight gain or low-sugar crashes of older options. The authors present the class as a leading direction for diabetes care.
Catalog record
| CREATOR | Xu He, Wei Zhao, PeiHang Li, YinJiang Zhang, GuoHua Li, HongYu Su, BiNan Lu, ZongRan Pang |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 41 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |